IDEXX Laboratories, Inc. $IDXX Shares Purchased by Achmea Investment Management B.V.

Achmea Investment Management B.V. grew its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 100.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,232 shares of the company’s stock after purchasing an additional 2,117 shares during the period. Achmea Investment Management B.V.’s holdings in IDEXX Laboratories were worth $2,270,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Stratos Wealth Partners LTD. increased its position in shares of IDEXX Laboratories by 1.7% in the second quarter. Stratos Wealth Partners LTD. now owns 1,051 shares of the company’s stock worth $564,000 after acquiring an additional 18 shares in the last quarter. Red Spruce Capital LLC boosted its stake in IDEXX Laboratories by 1.1% in the 2nd quarter. Red Spruce Capital LLC now owns 1,701 shares of the company’s stock worth $912,000 after purchasing an additional 19 shares during the period. Huntington National Bank boosted its stake in IDEXX Laboratories by 0.5% in the 2nd quarter. Huntington National Bank now owns 3,651 shares of the company’s stock worth $1,958,000 after purchasing an additional 19 shares during the period. Phoenix Financial Ltd. grew its position in IDEXX Laboratories by 1.7% during the 2nd quarter. Phoenix Financial Ltd. now owns 1,181 shares of the company’s stock worth $633,000 after purchasing an additional 20 shares in the last quarter. Finally, Rise Advisors LLC raised its position in IDEXX Laboratories by 3.9% during the second quarter. Rise Advisors LLC now owns 562 shares of the company’s stock valued at $301,000 after buying an additional 21 shares during the period. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Trading Down 0.7%

IDEXX Laboratories stock opened at $708.45 on Friday. The business’s 50-day simple moving average is $645.28 and its 200-day simple moving average is $578.23. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $735.00. The firm has a market capitalization of $56.68 billion, a PE ratio of 58.99, a PEG ratio of 4.06 and a beta of 1.62. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.79 and a current ratio of 1.11.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Monday, November 3rd. The company reported $3.40 EPS for the quarter, topping the consensus estimate of $3.14 by $0.26. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The company had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same period in the previous year, the business posted $2.80 EPS. The company’s revenue for the quarter was up 13.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Equities research analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on IDXX shares. Piper Sandler reaffirmed a “neutral” rating and set a $700.00 target price (up previously from $510.00) on shares of IDEXX Laboratories in a research note on Monday, August 11th. Jefferies Financial Group reaffirmed a “buy” rating and set a $830.00 price objective on shares of IDEXX Laboratories in a research report on Tuesday. Stifel Nicolaus set a $775.00 price target on IDEXX Laboratories in a research note on Monday. UBS Group boosted their price target on IDEXX Laboratories from $710.00 to $750.00 and gave the company a “neutral” rating in a research note on Tuesday. Finally, Morgan Stanley increased their price objective on IDEXX Laboratories from $765.00 to $805.00 and gave the stock an “overweight” rating in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, IDEXX Laboratories has an average rating of “Moderate Buy” and a consensus price target of $730.50.

Insider Buying and Selling

In related news, Director M Anne Szostak sold 2,187 shares of the company’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $647.33, for a total transaction of $1,415,710.71. Following the completion of the transaction, the director directly owned 262 shares in the company, valued at $169,600.46. This represents a 89.30% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Michael G. Erickson sold 406 shares of the stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $649.96, for a total transaction of $263,883.76. Following the completion of the sale, the executive vice president directly owned 11,287 shares of the company’s stock, valued at approximately $7,336,098.52. This trade represents a 3.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 3,793 shares of company stock valued at $2,467,430. 0.98% of the stock is owned by company insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.